Omid Seidizadeh: Honored to Join NordCoag 2026 to Celebrate 100 Years of von Willebrand Disease
Omid Seidizadeh, Research Leader of the A. Bianchi Bonomi Hemophilia and Thrombosis Center, reposted from NordCoag 2026 on LinkedIn:
”Thank you to the NordCoag 2026 organizers for the invitation.
Honored to speak in this special session marking 100 years since the first description of von Willebrand disease and to discuss advances linking pathophysiology, diagnostics, and patient management.
Looking forward to meeting colleagues and friends in Stockholm, 18 September, 2026.”
Quoting NordCoag 2026‘s post:
”One hundred years after von Willebrand disease was first described, there is still much to explore!
NordCoag 2026 final session is dedicated von Willebrand disease and will feature invited speaker Omid Seidizadeh (Milano, Italy) speaking on von Willebrand Disease: Linking Pathophysiology, Diagnostics, and Patient Management.
The session also includes colleagues from Karolinska University Hospital with August Lundholm on Insights from Approximately 300 von Willebrand Disease Genetic Investigations, and Anna Ågren on Acquired von Willebrand’s Disease.
Discover the full scientific programme at NordCoag 2026 website and sign up today. Welcome!”

Stay updated with Hemostasis Today.
-
Nov 16, 2026, 15:35Jim Hoffman: Could Blood Purification Change the Fight Against Cancer?
-
Nov 16, 2026, 15:16How Do Artificial Hearts Affect Platelet Function? – Platelets Journal
-
Nov 16, 2026, 15:10Assessing Coagulation Activation in DOAC – Treated Patients – JTH
-
Nov 16, 2026, 15:00Davide Antonio Mei: Should Anticoagulation Continue After AF Ablation?
-
Nov 16, 2026, 14:55Danielle Boyle: Beyond Platelet Counts – Why Patient Stories Matter
-
Nov 16, 2026, 14:28Jan Sloves: The Future of Vascular Ultrasound
-
Nov 16, 2026, 13:49Bahman Rasouli: A Rare Vascular Manifestation of Recurrent Papillary Thyroid Carcinoma
-
Nov 16, 2026, 13:28Muhammad Danyal: Platelet Patterns in Hepatitis B and C
-
Nov 16, 2026, 12:52Frank Nocken: Alzheimer’s Research Expands Beyond Amyloid-Based Treatments